Measuring disease-associated factors in sputum may be a less invasive way of tracking molecular changes in idiopathic pulmonary fibrosis (IPF) than bronchoalveolar washing, which involves sucking material from the lungs with a syringe, according to a study. Researchers found several factors in IPF patients at higher levels than in healthy people…
News
A secreted factor from bone marrow stem cells (BMSC-cm) improves the function of alveolar epithelial cells in repair and regeneration. These results support a potential therapeutic role for BMSC-cm released factors in idiopathic pulmonary fibrosis (IPF) and other lung diseases. The study “Hepatocyte growth factor secreted by bone marrow…
Patients with idiopathic pulmonary fibrosis (IPF) who rapidly gain weight may have a poorer prognosis than those with lesser weight gains, particularly if they never smoked. Researchers also linked to poorer survival a notable decline in lung function with one year, and a jump in the number of hospitalizations for airway problems. The study,…
Confo Therapeutics has received two multi-million-dollar research grants, one to identify new G-protein coupled receptor (GPCR) agonists to treat fibrosis and another to develop new applications for the company’s proprietary Confo technology. Flanders Innovation & Entrepreneurship (VLAIO) gave Confo a two-year €1.6 million ($1.7 million) grant for research into the GPCR…
Everyone suffers from stress from time to time but when you have a chronic disease, stress not only adds to your everyday burden but can often exacerbate the symptoms of your condition. While we can’t avoid stress altogether, there are ways that we help ourselves relax more and not let things…
Higher levels and activity of an enzyme, called urokinase plasminogen activator (uPA), were associated with fibrosis in lung tissue of patients with idiopathic pulmonary fibrosis (IPF). This suggests that uPA may be a target in treating lung fibrosis. The study, “The fibrogenic actions of lung fibroblast-derived urokinase: a potential drug target…
A lung fibrosis treatment based on a shark antibody is on the verge of entering a first clinical trial in patients. The treatment has shown promise in animal models of fibrosis, and offers hope for a therapy that is superior to current treatment approaches for lung fibrosis. Developed by Australian-based AdAlta, the compound is a…
People with idiopathic pulmonary fibrosis, and their caregivers, can learn more about this disease and its care using a free and online interactive program developed by ProPatient, the Pulmonary Fibrosis Foundation (PFF), and the Academy for Continued Healthcare Learning (ACHL). Called “Idiopathic Pulmonary Fibrosis: Partnering with Your Doctor,” the educational program offers…
By developing a drug that blocks a molecule — going under the curious name, porcupine — Redx Pharma hopes to develop a new kind of treatment for idiopathic pulmonary fibrosis. The company’s porcupine program also aims to come up with drugs that can improve responses to cancer immunotherapy. “We’re…
When you think of someone who has a lung disease, such as idiopathic pulmonary fibrosis (IPF), it is easy to understand that physical exhaustion is likely a primary side effect. What may not be so easy to understand, however, is the mental exhaustion that comes with having…
